Correction to "Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology"

Jie Wang,Robert Dallmann,Renquan Lu,Jing Yan,Jérôme Charmet

DOI: https://doi.org/10.1021/acssensors.3c01053

IF: 8.9

2023-06-08

ACS Sensors

Abstract:ACS Sens . 2023 Jun 7. doi: 10.1021/acssensors.3c01053. Online ahead of print. NO

chemistry, multidisciplinary, analytical,nanoscience & nanotechnology

What problem does this paper attempt to address?

Flow Rate Independent Multiscale Liquid Biopsy for Precision Oncology

Jing Yan,Jie Wang,Robert Dallmann,Renquan Lu,Jérôme Charmet

DOI: https://doi.org/10.1021/acssensors.2c02577

2022-11-14

Abstract:Immunoaffinity-based liquid biopsies of circulating tumor cells (CTCs) hold great promise for cancer management, but typically suffer from low throughput, relative complexity and post-processing limitations. Here we address these issues simultaneously by decoupling and independently optimizing the nano-, micro- and macro-scales of an enrichment device that is simple to fabricate and operate. Unlike other affinity-based devices, our scalable mesh approach enables optimum capture conditions at any flow rate, as demonstrated with constant capture efficiencies, above 75% between 50-200 uL/min. The device achieved 96% sensitivity and 100% specificity when used to detect CTCs in the blood of 79 cancer patients and 20 healthy controls. We demonstrate its post processing capacity with the identification of potential responders to immune checkpoint inhibition therapy and the detection of HER2 positive breast cancer. The results compare well with other assays, including clinical standards. This suggests that our approach, which overcomes major limitations associated with affinity-based liquid biopsies, could help improve cancer management.

Quantitative Methods
Correction to "Strategy for Microscale Extraction and Proteome Profiling of Peripheral Blood Mononuclear Cells"

Li Yang,Shuang Weng,Xiaohong Qian,Mingchao Wang,Wantao Ying

DOI: https://doi.org/10.1021/acs.analchem.3c03282

IF: 7.4

2023-08-04

Analytical Chemistry

Abstract:Anal Chem . 2023 Aug 3. doi: 10.1021/acs.analchem.3c03282. Online ahead of print. NO

chemistry, analytical
A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

Guangliang Li,Lisong Teng

DOI: https://doi.org/10.2217/fon.14.16

2014-01-01

Future Oncology

Abstract:A major challenge in cancer therapy lies in its complexity and heterogeneity, with increasing recognition of many tumor subtypes that have different biological characteristics and responses to therapies. To effectively address this challenge, personalized medicine has been the 'vogue' currently. Dissecting the detailed clonal architecture of cancer by cancer genomics, which holds the promise of personalized medicine, has significant clinical implications. Substantial advances have been made in DNA-based, high-throughput genomic technologies. However, current methods are still in its infancy, significantly limited by error rates, low cell throughput, high cost and labor intensive. The study under evaluation develops a superior strategy for a comprehensive interrogation of the complex genomics of cancer cells by using multiplex-targeted DNA amplification from flow-sorted single cells followed by high-throughput quantitative PCR using the BioMark HD microfluidic platform. The platform demonstrated a successful rate of approximately 75%, a highly efficient single-cell sorting rate of 96-98%, a high-throughput analysis of 200-300 leukemic cells, and was able to simultaneously detected chimeric fusion genes, copy number alterations and single-nucleotide variants in a single cell sample.
Correction to "Liquid Metal pH Morphology Sensor Used for Biological Microenvironment Detection"

Yang Wang,Liangtao Li,Shuting Liang,Kang Sun,Caicai Jiao,Qian Wang,Liang Hu

DOI: https://doi.org/10.1021/acs.analchem.3c00770

IF: 7.4

2023-03-08

Analytical Chemistry

Abstract:Anal Chem . 2023 Mar 6. doi: 10.1021/acs.analchem.3c00770. Online ahead of print. NO

chemistry, analytical
Erratum: Single-band Upconversion Nanoprobes for Multiplexed Simultaneous in Situ Molecular Mapping of Cancer Biomarkers

Zhou, Lei,Wang, Rui,Yao, Chi,Li, Xiaomin,Wang, Chengli,Zhang, Xiaoyan,Xu, Congjian,Zeng, Aijun,Zhao, Dongyuan,Zhang, Fan

DOI: https://doi.org/10.1038/ncomms8350

IF: 16.6

2015-01-01

Nature Communications

Abstract:Nature Communications 6: Article number: 6938 (2015); Published 24 April 2015; Updated 12 June 2015. This Article contains errors in the author affiliation 1 and in Figs 2 and 6. The correct details for affiliation 1 are given below: 1Department of Chemistry and Laboratory of Advanced Materials, iChEm (Collaborative Innovation Center of Chemistry for Energy Materials), State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200433, China.
Corrigendum: Interpreting flow cytometry with caution: a case report of follicular lymphoma in leukemic phase misdiagnosed as chronic lymphocytic leukemia

Yuan Ren,Congwei Jia,Miao Chen,Wei Wang,Wei Zhang

DOI: https://doi.org/10.3389/fonc.2023.1229649

IF: 4.7

2023-06-06

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1170598.].

oncology
Correction: Continuous inertial microparticle and blood cell separation in straight channels with local microstructures (Lab Chip (2016) 16 (532-542))

Zhenlong Wu,Yu Chen,Moran Wang,Aram J. Chung

DOI: https://doi.org/10.1039/c6lc90035f

IF: 7.517

2016-01-01

Lab on a Chip

Abstract:Correction for 'Continuous inertial microparticle and blood cell separation in straight channels with local microstructures' by Zhenlong Wu et al., Lab Chip, 2016, 16, 532-542.
Optimizing Access to Liquid Biopsy in the Present and Future Cancer Landscape

Arielle J. Medford,Leif W. Ellisen

DOI: https://doi.org/10.1200/po.23.00609

2024-01-01

JCO Precision Oncology

Abstract:We discuss a recent manuscript providing recommendations to improve use and access for liquid biopsy in oncology.

oncology
Correction to "Janus ACSP Nanoparticle for Synergistic Chemodynamic Therapy and Radiosensitization"

Mingzhen Xu,Yuyi Qian,Xinyi Li,Bingxin Gu,Simin He,Xin Lu,Shaoli Song

DOI: https://doi.org/10.1021/acsami.4c07552

IF: 9.5

2024-06-06

ACS Applied Materials & Interfaces

Abstract:ACS Appl Mater Interfaces . 2024 Jun 5. doi: 10.1021/acsami.4c07552. Online ahead of print. NO

materials science, multidisciplinary,nanoscience & nanotechnology
Correction: Open-flow microperfusion combined with mass spectrometry for in vivo liver lipidomic analysis

Tuo Li,Hui Yang,Xing Li,Yinzhu Hou,Yao Zhao,Wenjing Wu,Lingyu Zhao,Fuyi Wang,Zhenwen Zhao

DOI: https://doi.org/10.1039/d4an90067g

2024-08-26

The Analyst

Abstract:Correction for 'Open-flow microperfusion combined with mass spectrometry for in vivo liver lipidomic analysis' by Tuo Li et al. , Analyst , 2021, 146 , 1915–1923, https://doi.org/10.1039/D0AN02189J.

chemistry, analytical
Toward precision oncology: SERS microfluidic systems for multiplex biomarker analysis in liquid biopsy

Karthik Balaji Shanmugasundaram,Junrong Li,Abu Ibn Sina,Alain Wuethrich,Matt Trau

DOI: https://doi.org/10.1039/d1ma00848j

2022-01-01

Materials Advances

Abstract:Liquid biopsy-based diagnosis in precision oncology exhibits significant advantages over the traditional tissue biopsies by offering dynamic assessment of tumour heterogeneity, minimally invasive procedures for frequent sampling, and cost-effective tests.
Supplementary Methods, Figures 1-14 from A Microfluidic Platform for Systems Pathology: Multiparameter Single-Cell Signaling Measurements of Clinical Brain Tumor Specimens

Jing Sun,Michael D. Masterman-Smith,Nicholas A. Graham,Jing Jiao,Jack Mottahedeh,Dan R. Laks,Minori Ohashi,Jason DeJesus,Ken-ichiro Kamei,Ki-Bum Lee,Hao Wang,Zeta T.F. Yu,Yi-Tsung Lu,Shuang Hou,Keyu Li,Max Liu,Nangang Zhang,Shutao Wang,Brigitte Angenieux,Eduard Panosyan,Eric R. Samuels,Jun Park,Dirk Williams,Vera Konkankit,David Nathanson,R. Michael van Dam,Michael E. Phelps,Hong Wu,Linda M. Liau,Paul S. Mischel,Jorge A. Lazareff,Harley I. Kornblum,William H. Yong,Thomas G. Graeber,Hsian-Rong Tseng

DOI: https://doi.org/10.1158/0008-5472.22383531

2023-01-01

Abstract:Supplementary Methods, Figures 1-14 from A Microfluidic Platform for Systems Pathology: Multiparameter Single-Cell Signaling Measurements of Clinical Brain Tumor Specimens
Abstract 5018: Evaluation of whole blood fractionation conditions for optimal liquid biopsy NGS applications

MADHU JASTI,Sergio Hernandez,Nick Siepert,Lokesh Kodandaramaswamy,Thilanka Jayaweera,Jeoffrey Schageman,Angie Cheng,Susanne Lopez,Miao Der Chen

DOI: https://doi.org/10.1158/1538-7445.am2024-5018

IF: 11.2

2024-03-24

Cancer Research

Abstract:"For research use only. Not for diagnostic procedures." Introduction: Liquid biopsy is a non-invasive alternative to tissue biopsies for cancer profiling using cell-free total nucleic acids (cfTNA; including cell free DNA (cfDNA) and cell free RNA (cfRNA)), the biological analytes derived from tumor cells floating in blood. However, it is crucial to optimize the whole blood fractionation workflows, since limited access to a suitable centrifuge at blood collection sites poses a challenge to this critical fractionation step, causing delays in processing the blood, leading to decreased sensitivity of variant detection and increased occurrence of false positives. Current study shows a systematic comparison of the effects of 8 different blood fractionation conditions for spin speeds, temperatures and duration on the levels of cfTNA derived from K2-EDTA-derived blood from multiple healthy and non-small cell lung cancer (NSCLC) donors, using next generation sequencing (NGS). Methods: CfTNA from K2-EDTA derived plasma was isolated using the MagMAXTM Cell-Free Total Nucleic Acid kit and the GenexusTM Cell free total nucleic acid kit, utilizing the KingFisher TM Flex and GenexusTMpurification systems. Yield and integrity of cfTNA isolated was evaluated by QubitTM, Agilent Tapestation and quantitative real time PCR (qRT-PCR). Furthermore, the impact of these test conditions on quality control specifications of DNA and RNA was assessed by performing sequencing on an Ion TorrentTM GenexusTM sequencing instrument using the AmpliSeqTM HD target amplification assay, that reports sequence variations in DNA for 42 cancer related genes and RNA in 7 cancer related genes. Results: Results showed comparable performance for all the 8 blood fractionation conditions tested, for yield and cfDNA profiles compared to control condition, indicating that there is no significant impact of these conditions on either yield or integrity of the cfDNA isolated. In addition, NGS data also showed that on target reads and median molecular coverage for DNA are comparable for all the conditions tested. However, sequencing data demonstrated that one test condition showed significantly better performance for RNA quality control specifications in terms of RNA mapped reads and molecular coverage for process controls used in the assay, compared to all other conditions tested. Conclusion: Data suggests that one of the whole blood fractionation conditions tested impact the cfRNA recovery from plasma without negatively affecting the yield, and integrity of isolated cfDNA and shows increased sensitivity for RNA process controls in NGS. Citation Format: MADHU JASTI, Sergio Hernandez, Nick Siepert, Lokesh Kodandaramaswamy, Thilanka Jayaweera, Jeoffrey Schageman, Angie Cheng, Susanne Lopez, Miao Der Chen. Evaluation of whole blood fractionation conditions for optimal liquid biopsy NGS applications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5018.

oncology
Optimizing The Flow Cytometric Analysis Of Cell Signaling In Heterogeneous Samples

guojian gao,christopher coveney,xiao wang,xiaowei wu,aili wei,xiangdong ji,lori anderson,nikesh kotecha,jurg rohrer,erika odonnell

DOI: https://doi.org/10.1158/1538-7445.AM2012-157

IF: 11.2

2012-01-01

Cancer Research

Abstract:Unlike conventional biochemical methods for cell signaling analysis, analyzing protein levels by flow cytometry allows measurements to be made at the single-cell level. Multiparameter flow cytometry provides a powerful tool for the analysis of protein expression and phosphorylation status within complex populations, such as those found in lymphoid tissues or blood. However, different intracellular and cell surface proteins often require different conditions for optimal detection, creating challenges for analyzing multiple protein types in a single sample. To facilitate the design of multiparameter staining panels for analysis of intracellular and cell surface proteins, we tested over 250 fluorescently conjugated antibodies in cells fixed and permeabilized under various conditions. Multiple fluorescent conjugates of each antibody were tested in human PBMCs, human whole blood, mouse spleen, and/or mouse bone marrow following fixation with BD Phosflow™ Lyse/Fix or BD Cytofix™ Fixation Buffer and permeabilization with one of the four BD Phosflow™ Perm buffers. These studies demonstrated that certain intracellular epitopes required harsh permeabilization conditions for optimal detection, whereas others were detectable under milder conditions. Surface marker stains often required optimization, particularly under harsh permeabilization conditions. Factors such as antibody clone, fluorophore, and concentration had a considerable impact on staining resolution, and alternative staining protocols were required for optimal staining of some surface markers. To facilitate the optimization of fixation, permeabilization, and staining conditions for multiparameter flow cytometry, experimental data and protocols from this study are available through an interactive database freely accessible at www.cytobank.org/facselect. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 157. doi:1538-7445.AM2012-157
Correction: A layered cancer-on-a-chip system for anticancer drug screening and disease modeling

Magdalena Flont,Zuzanna Mackiewicz,Marta Białek,Artur Dybko,Elżbieta Jastrzębska

DOI: https://doi.org/10.1039/d4an90068e

2024-09-03

The Analyst

Abstract:Correction for 'A layered cancer-on-a-chip system for anticancer drug screening and disease modeling' by Magdalena Flont et al. , Analyst , 2023, 148 , 5486–5495, https://doi.org/10.1039/D3AN00959A.

chemistry, analytical
Abstract 2432: Improved liquid biopsy assay performance using sequencing by binding (SBB)

Dan Nasko,Phillip Pham,Stuti Joshi,Kristi Kim,Nairi Pezeshkian,Young Kim,Alexandra Sockell,Jonas Korlach

DOI: https://doi.org/10.1158/1538-7445.am2024-2432

IF: 11.2

2024-03-23

Cancer Research

Abstract:Liquid biopsy is revolutionizing the field of early cancer detection research through non-invasive detection of tumor DNA in the blood. However, existing liquid biopsy assays are limited in their sensitivity for ctDNA detection at low variant allele frequencies (VAFs), with most relying on extreme sequencing depth and computational error correction to separate the true ctDNA signal from background errors. This limitation is particularly problematic in the area of early cancer detection, in which expected ctDNA allele frequencies are extremely low. Novel strategies are therefore needed to help improve liquid biopsy assay sensitivity and reduce per-sample sequencing requirements. Here we describe PacBio's application of the Onso short-read sequencing system to enable detection of ctDNA at low VAFs using the SeraCare Complete ctDNA Mutation Mix reference standard. The Onso system makes use of a novel sequencing by binding (SBB) method to achieve up to 15x greater quality scores, with ≥90% of reads at Q40 or above. We performed targeted capture and sequencing of libraries prepared from the SeraCare reference mix diluted into WT human DNA at the following VAFs: 0.00% (WT), 0.05%, 0.10%, 0.25%, and 0.50%, and compared the sensitivity at each VAF for SBB compared to a competitor method using sequencing by synthesis (SBS) at varying sequencing depths. We observed superior sensitivity for ctDNA detection at low VAFs (0.05%, 0.1%) using SBB at half the sequencing depth compared to SBS, in part due to reduced false positive calling in the WT sample for SBB. Furthermore, SBB was able to achieve comparable sensitivity results to SBS using four-fold less sequencing, and without the use of computational error correction. Finally, combining SBB with computational error-correction methods boosted sensitivity even further, suggesting an additive value for these technologies. Taken together, our results demonstrate the potential of SBB to improve upon existing methods of liquid biopsy and better enable research on early cancer detection. Citation Format: Dan Nasko, Phillip Pham, Stuti Joshi, Kristi Kim, Nairi Pezeshkian, Young Kim, Alexandra Sockell, Jonas Korlach. Improved liquid biopsy assay performance using sequencing by binding (SBB) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2432.

oncology
Abstract 323: Optimization of a liquid biopsy assay to accommodate low cfDNA samples and increase throughput

Michael Salmans,Dasom Kim,Andrew Carson,Mengchi Wang,Byung In Lee,Bryan Leatham

DOI: https://doi.org/10.1158/1538-7445.am2024-323

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Molecular testing that interrogates cell free DNA (cfDNA) from plasma has significant potential value across the cancer care continuum, including early cancer detection, driver mutation identification, and disease recurrence monitoring. To achieve this potential, liquid biopsy assays must be optimized to address multiple challenges. For one, cfDNA quantity in the blood is highly variable, with different amounts present depending on malignancy and stage of progression. This requires optimization to detect low concentrations of circulating tumor DNA (ctDNA) and to accommodate variable tumor fractions. In addition, minimizing assay costs will improve test accessibility and adoption. To address these issues, Genece Health is optimizing their lung cancer liquid biopsy assay to accommodate minimal cfDNA input into library preparation. Furthermore, Genece is testing algorithms that tolerate reduced read depths from low-pass whole genome sequencing (LP-WGS) while maintaining high performance. The Genece lung cancer liquid biopsy assay profiles fragment end-motif and size (FEMS) and fragment coverage signals using LP-WGS (Illumina) and proprietary machine learning algorithms. This study first tested the frequency of end motifs in pooled ctDNA after modifying library preparation (IDT) to reduce reagent volumes from 1X down to 0.5X, 0.25X, and 0.1X of manufacturer specification. A range of cfDNA input from 0.25 ng to 6 ng was tested with each library preparation volume. In addition, LP-WGS read coverage from 5X to 1X was evaluated to assess impact on end motif frequency and assay sensitivity. Performance characterization was further evaluated with a cohort of 50 clinical lung cancer and 100 healthy donor plasma samples tested at 1X and 0.25X library reagent volume. We observed an expected increase in library complexity at higher cfDNA input and library reagent volume. Assay performance was minimally impacted by variable cfDNA input and library reagent volume. However, reducing sequencing read depth is tolerated down to 1.25X depth before increasing the variability of end motif frequencies. These observations are corroborated in the 150 clinical sample cohort. This data shows that by altering standard library preparation conditions and reducing unique read depth, liquid biopsy assays can accommodate a wider range of cfDNA, while concurrently decreasing overall costs. Citation Format: Michael Salmans, Dasom Kim, Andrew Carson, Mengchi Wang, Byung In Lee, Bryan Leatham. Optimization of a liquid biopsy assay to accommodate low cfDNA samples and increase throughput [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 323.

oncology
Correction to "α 3 β 1 Integrin-Targeting Polymersomal Docetaxel as an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment"

Yan Zou,Yinping Sun,Beibei Guo,Yaohua Wei,Yifeng Xia,Zhenyuan Huangfu,Fenghua Meng,Jan C. M. van Hest,Jiandong Yuan,Zhiyuan Zhong

DOI: https://doi.org/10.1021/acsami.4c07760

IF: 9.5

2024-05-22

ACS Applied Materials & Interfaces

Abstract:ACS Appl Mater Interfaces . 2024 May 21. doi: 10.1021/acsami.4c07760. Online ahead of print. NO

materials science, multidisciplinary,nanoscience & nanotechnology
Liquid biopsy technologies based on membrane microfluidics: High‐yield purification and selective quantification of biomarkers in nanocarriers

Ceming Wang,Satyajyoti Senapati,Hsueh‐Chia Chang

DOI: https://doi.org/10.1002/elps.202000015

2020-04-09

Electrophoresis

Abstract:<p>Liquid biopsy, screening cancer non‐invasively and frequently by detecting and quantifying molecular markers in physiological fluids, would significantly improve cancer survival rate but it remains a distant goal. The key obstacles presented by the highly heterogeneous samples are rapid/high‐yield purification and precise/selective marker capture by their antibody and oligo probes. As irregular expressions of these molecular biomarkers are the key signals, quantifying only those from the cancer cells would greatly enhance the performance of the screening tests. The recent discovery that the biomarkers are carried by nanocarriers, such as exosomes, with cell‐specific membrane proteins suggests that such selection may be possible, although a new suite of fractionation and quantification technologies would need to be developed. Although under‐appreciated, membrane microfluidics has made considerable contributions to resolving these issues. We review the progress made so far, based on ion‐selective, track‐etched and gel membranes and advanced electrophoretic and nano‐filtration designs, in this perspective and suggest future directions.</p><p>This article is protected by copyright. All rights reserved</p>

biochemical research methods,chemistry, analytical
Abstract 2334: Computational methods for optimizing marker selection, clonal lineage reconstruction, and longitudinal tracking of clonal dynamics via circulating tumor DNA (ctDNA)

Xuecong Fu,Yueqian Deng,Zhicheng Luo,William Laframboise,David Bartlett,Russell Schwartz

DOI: https://doi.org/10.1158/1538-7445.am2024-2334

IF: 11.2

2024-03-24

Cancer Research

Abstract:Background: Technologies for blood-based profiling of tumor DNA ("liquid biopsy") have offered great prospects for non-invasive early cancer diagnosis, treatment monitoring, and clinical guidance, but further advances in computational models and data analysis to optimize monitoring protocols and develop liquid biopsy as a robust quantitative assay of tumor clonal evolution. Methods: We propose new computational methods to improve our ability to characterize tumor clonal dynamics from circulating tumor DNA (ctDNA). Our methods address how to apply ctDNA assays most effectively to two distinct questions in profiling tumor clonal dynamics: 1) How to apply longitudinal ctDNA data to refine phylogenetic tree models of clonal evolution, and 2) how to most effectively characterize changes in clonal frequencies that may be indicative of treatment response or tumor progression. We pose these questions computationally in terms of a probabilistic framework for optimally identifying maximum likelihood markers for the preceding tasks and applying measured marker concentrations to their solution. We apply this framework by first evaluating the distribution of plausible clonal lineage models using bootstrap samples over pre-treatment tissue-based genetic variation data, then refining these lineage models and the clonal frequencies we can infer from them over successive longitudinal samples of selected markers. Results: We tested our method on synthetic data under various model assumptions and showed the method to be effective at refining distribution tree models and clonal frequencies over longitudinal samples so as to minimize measures of tree distance relative to the ground truth. We further apply the methods to a real ovarian cancer case and show their ability to develop and refine a clonal lineage model and assess clonal frequencies. Conclusion: Our methods show the power of ctDNA assays in conjunction with computational optimization to lead to improved marker selection, clonal lineage reconstruction, and tracking of clonal dynamics, with potential for more precise and quantitative profiling of tumor progression enabling improved clinical decision-making. Citation Format: Xuecong Fu, Yueqian Deng, Zhicheng Luo, William Laframboise, David Bartlett, Russell Schwartz. Computational methods for optimizing marker selection, clonal lineage reconstruction, and longitudinal tracking of clonal dynamics via circulating tumor DNA (ctDNA) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2334.

oncology

Correction to "Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology"

Flow Rate Independent Multiscale Liquid Biopsy for Precision Oncology

Correction to "Strategy for Microscale Extraction and Proteome Profiling of Peripheral Blood Mononuclear Cells"

A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

Correction to "Liquid Metal pH Morphology Sensor Used for Biological Microenvironment Detection"

Erratum: Single-band Upconversion Nanoprobes for Multiplexed Simultaneous in Situ Molecular Mapping of Cancer Biomarkers

Corrigendum: Interpreting flow cytometry with caution: a case report of follicular lymphoma in leukemic phase misdiagnosed as chronic lymphocytic leukemia

Correction: Continuous inertial microparticle and blood cell separation in straight channels with local microstructures (Lab Chip (2016) 16 (532-542))

Optimizing Access to Liquid Biopsy in the Present and Future Cancer Landscape

Correction to "Janus ACSP Nanoparticle for Synergistic Chemodynamic Therapy and Radiosensitization"

Correction: Open-flow microperfusion combined with mass spectrometry for in vivo liver lipidomic analysis

Toward precision oncology: SERS microfluidic systems for multiplex biomarker analysis in liquid biopsy

Supplementary Methods, Figures 1-14 from A Microfluidic Platform for Systems Pathology: Multiparameter Single-Cell Signaling Measurements of Clinical Brain Tumor Specimens

Abstract 5018: Evaluation of whole blood fractionation conditions for optimal liquid biopsy NGS applications

Optimizing The Flow Cytometric Analysis Of Cell Signaling In Heterogeneous Samples

Correction: A layered cancer-on-a-chip system for anticancer drug screening and disease modeling

Abstract 2432: Improved liquid biopsy assay performance using sequencing by binding (SBB)

Abstract 323: Optimization of a liquid biopsy assay to accommodate low cfDNA samples and increase throughput

Correction to "α 3 β 1 Integrin-Targeting Polymersomal Docetaxel as an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment"

Liquid biopsy technologies based on membrane microfluidics: High‐yield purification and selective quantification of biomarkers in nanocarriers

Abstract 2334: Computational methods for optimizing marker selection, clonal lineage reconstruction, and longitudinal tracking of clonal dynamics via circulating tumor DNA (ctDNA)